Serrapeptase (serratiopeptidase) is a proteolytic enzyme supplement derived from bacteria originally found in silkworms. It is widely used in Ireland for inflammation, pain, and post-surgical swelling — see our full Serrapeptase Evidence Review for the efficacy data. This page focuses specifically on the safety profile: what adverse events have been documented, what interactions exist, and how to assess risk before taking it.
Published clinical trials of serrapeptase for durations ranging from two weeks to six months have generally reported a benign short-term safety profile. In the most commonly studied doses (10–60 mg per day), the incidence of serious adverse events in trial populations has been very low. The most commonly reported adverse events are:
These are typical minor adverse effects seen with enzyme supplements generally. They do not represent serious safety signals in otherwise healthy adults at standard doses.
Trials beyond 12 months of serrapeptase supplementation are essentially absent from the published literature. This is a genuine limitation. We do not have robust long-term safety data comparable to what exists for well-studied medications. The historical use of serrapeptase (as a pharmaceutical preparation) in Japan and Germany for several decades without signals of major harm provides some reassurance — but this is anecdotal and regulatory rather than rigorously studied. Anyone contemplating indefinite long-term supplementation should periodically reassess the need with their healthcare provider.
The most clinically important safety concern with serrapeptase is its effect on haemostasis — the body's clotting system. Serrapeptase has documented fibrinolytic activity: it degrades fibrin, a key structural protein in blood clots. This is the same mechanism that underlies any anti-inflammatory benefit it might have — but it also means the enzyme has the potential to impair normal clotting and amplify the effects of anticoagulant medications.
The interaction with blood-thinning drugs is not merely theoretical. The following mechanisms and evidence support treating this as a real clinical concern:
Warfarin (Coumadin) exerts its anticoagulant effect by inhibiting vitamin K-dependent clotting factors. Its therapeutic window is narrow — small changes in the balance of anticoagulation can lead to either clotting events (if under-anticoagulated) or serious bleeding (if over-anticoagulated). Because serrapeptase independently degrades fibrin and may inhibit platelet aggregation, adding it to a warfarin regimen unpredictably shifts the haemostatic balance toward bleeding. Several published case reports have linked proteolytic enzyme supplementation (including serrapeptase) with haemorrhagic complications in warfarin patients. The interaction is plausible, documented in case reports, and consistent with basic pharmacology.
The newer direct oral anticoagulants — apixaban (Eliquis), rivaroxaban (Xarelto), dabigatran (Pradaxa), and edoxaban — are increasingly prescribed in Ireland for atrial fibrillation and VTE prevention. These drugs are already potent anticoagulants with predictable pharmacology, and laboratory and case-based evidence suggest that fibrinolytic supplements can interact with these agents as well, increasing bleeding risk. Unlike warfarin, NOACs are not routinely INR-monitored, making it harder to detect a dangerous interaction early.
Aspirin (75–300 mg daily), clopidogrel, ticagrelor, and prasugrel inhibit platelet function. Adding a fibrinolytic supplement to existing antiplatelet therapy compounds the impairment of clot formation. This is particularly relevant for people on dual antiplatelet therapy (e.g., aspirin + clopidogrel post-coronary stent) where bleeding risk is already elevated.
| Interaction | Risk Level | Notes |
|---|---|---|
| Warfarin | HIGH RISK — Avoid | Case reports of haemorrhage; INR unpredictably affected |
| Apixaban / Rivaroxaban / Dabigatran | HIGH RISK — Avoid | No INR monitoring to catch interaction; additive fibrinolysis |
| Aspirin (daily antiplatelet dose) | MODERATE RISK | Additive antiplatelet + fibrinolytic effect |
| Clopidogrel / Ticagrelor | MODERATE RISK | As above — antiplatelet compound risk |
| Nattokinase / Bromelain (stacking) | MODERATE RISK | Additive fibrinolytic enzymes; no safety data for combinations |
| NSAIDs (ibuprofen, naproxen) | LOW-MODERATE | NSAIDs also inhibit platelet function; additive effect theoretical |
Due to the fibrinolytic activity, serrapeptase should be discontinued at least two weeks before any surgical or invasive dental procedure. Surgeons and anaesthetists should be informed of all supplements being taken preoperatively. Many patients do not disclose supplement use — a potentially dangerous omission.
In Japan, where serrapeptase was used as a pharmaceutical, rare cases of eosinophilic pneumonia (a form of allergic lung reaction) were documented in post-marketing surveillance. This led to regulatory caution in Japan regarding long-term use. While the absolute incidence was low, the signal reinforces the importance of stopping serrapeptase and seeking medical attention if new respiratory symptoms (cough, breathlessness, fever) develop during supplementation.
For a healthy adult under 60 with no cardiovascular disease, no medication, and no bleeding history, serrapeptase at standard doses (80,000–250,000 IU/day) for a defined short-term course is likely to be well-tolerated. The risk-benefit profile shifts significantly for anyone with relevant medications or conditions — in those cases, the interaction risk clearly outweighs the modest and uncertain clinical benefit of the supplement.
Serrapeptase has acceptable short-term safety in healthy adults at standard doses. The absence of long-term data, the genuine bleeding interaction with anticoagulants, and the rare but documented lung reaction signal mean it should not be treated as risk-free. Always disclose serrapeptase use to your GP, pharmacist, and any treating specialist. Do not purchase and self-administer without first reviewing your current medications.
Serrapeptase has a reasonable short-term safety record in appropriate populations — but "appropriate" is a meaningful qualifier. The anticoagulant interaction is a serious safety concern, not a minor footnote. If you take blood-thinning medication of any kind, the answer to "can I take serrapeptase?" is: not without explicit medical review. For everyone else, standard short-term use with awareness of the surgical pre-cessation requirement represents the most risk-managed approach.